Rarity PBC Secures $4.6M Seed Round to Accelerate Gene‑Therapy Development

Why It Matters

The funding gives Rarity the resources to fast‑track a potentially first‑in‑class therapy for a rare disease, addressing an unmet patient need and signaling confidence in the public‑benefit biotech model, which could attract further capital to the sector.

Deal Summary

Los Angeles‑based public benefit corporation Rarity PBC announced a $4.6 million seed financing to advance its lead gene‑therapy program for rare diseases. The round was led by biotech investor Steve Oliveira of Nemean Asset Management.